{"disease":{"id":"rheumatoid-arthritis-ra","name":"rheumatoid arthritis ra"},"drugs":{"marketed":[{"drug_id":"upadacitinib","indication_name":"Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"tofacitinib-xeljanz","indication_name":"Rheumatoid Arthritis (RA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tofacitinib (Xeljanz)","generic_name":"tofacitinib-xeljanz","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK3","drug_class":"Janus Kinase Inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and ankylosing spondylitis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and Crohn's disease and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and Crohn's disease and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and ankylosing spondylitis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and rheumatoid arthritis and ankylosing spondylitis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and rheumatoid arthritis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, rheumatoid arthritis, Crohn's disease, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, hidradenitis suppurativa, and atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tocilizumab","indication_name":"Rheumatoid Arthritis (RA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Roactemra","generic_name":"tocilizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Interleukin-6 receptor","drug_class":"Interleukin-6 Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation."},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, hidradenitis suppurativa, atopic dermatitis, and plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":25,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06670183","title":"Dietary Factors and Rheumatoid Arthritis Risk in the UK Biobank","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500000,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT03835780","title":"The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":266890,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT05421442","title":"A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database","phase":"","overall_status":"COMPLETED","enrollment_count":38396,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06670144","title":"Diet and Rheumatoid Arthritis Risk in the United Kingdom Women's Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":35372,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT05603728","title":"Exactech Shoulder Post Market Clinical Follow-up Study","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Exactech","has_results":false},{"nct_id":"NCT07463937","title":"A RWS of SC MTX in Chinese RA Patients","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07484243","title":"Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Yuanyuan Zhang","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT04340115","title":"Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ Tablets","phase":"","overall_status":"COMPLETED","enrollment_count":4211,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT07363980","title":"Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":4000,"lead_sponsor_name":"Ellen Margrethe Hauge","has_results":false},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT03971253","title":"Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT04541810","title":"A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":2369,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04798625","title":"Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Diakonhjemmet Hospital","has_results":false},{"nct_id":"NCT03662919","title":"One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":2274,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT04497597","title":"A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":1532,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03631225","title":"The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Sequenom, Inc.","has_results":false},{"nct_id":"NCT07221890","title":"A Trial of Academic Detailing to Promote Prescribing of Biosimilars","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1325,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05190484","title":"bIosimilar of aDalimumab, an European evAluation","phase":"","overall_status":"UNKNOWN","enrollment_count":1050,"lead_sponsor_name":"Fresenius Kabi","has_results":false},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT04089514","title":"A Real-world Study of Imraldi® Use","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT06417138","title":"Comparative Effectiveness of Different Drugs Used to tr€at Patients in Rheumatoid Arthritis Saudi Database (RASD)\"","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Umm Al-Qura University","has_results":false},{"nct_id":"NCT03729674","title":"Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT06785883","title":"Screening Anxiety and Depression Among Patients with Chronic Musculoskeletal Pain Within Physiotherapy Practices","phase":"","overall_status":"COMPLETED","enrollment_count":750,"lead_sponsor_name":"KU Leuven","has_results":false},{"nct_id":"NCT06599658","title":"COVID-19 Booster and IIV Schedule in Immunocompromised Hosts","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":660,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT03086343","title":"A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":657,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT06726096","title":"Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":615,"lead_sponsor_name":"Beijing VDJBio Co., LTD.","has_results":false},{"nct_id":"NCT03074656","title":"The Norwegian Drug Monitoring Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Diakonhjemmet Hospital","has_results":false},{"nct_id":"NCT06072287","title":"The Living With a Long-Term Condition Study","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"King's College London","has_results":false},{"nct_id":"NCT03430388","title":"Yellow Fever Vaccine in Patients With Rheumatic Diseases","phase":"NA","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT04997005","title":"The Medacta International AMIStem-P Post-Marketing Surveillance Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":550,"lead_sponsor_name":"Medacta International SA","has_results":false},{"nct_id":"NCT05186168","title":"Corin MiniHip and Trinity Cup Clinical Surveillance Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":546,"lead_sponsor_name":"Corin","has_results":false},{"nct_id":"NCT02466217","title":"Phenomics in Autoimmune and Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":537,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04267536","title":"An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiveness of Upadacitinib as Monotherapy or in Combination With MTX in Adult Participants With Rheumatoid Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":534,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT07188285","title":"Mass Spectrometry-based Immune Profiling in Autoimmune Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT03063593","title":"UK Infinity, Post-Market Clinical Follow-up Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Stryker Trauma and Extremities","has_results":false},{"nct_id":"NCT06167226","title":"Understanding Ayurveda Disease Conditions and Treatment Responses","phase":"","overall_status":"COMPLETED","enrollment_count":497,"lead_sponsor_name":"Ayurai Private Limited","has_results":false},{"nct_id":"NCT07087912","title":"Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":477,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT04888585","title":"Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":473,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT07277491","title":"Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity","phase":"","overall_status":"RECRUITING","enrollment_count":460,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT03664791","title":"Vanguard Rocc Post Market Surveillance","phase":"","overall_status":"UNKNOWN","enrollment_count":450,"lead_sponsor_name":"Zimmer Biomet","has_results":false},{"nct_id":"NCT04033588","title":"Freedom® Total Knee System for Treatment of Osteoarthritis, Rheumatoid Arthritis or Post-traumatic Arthritis","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":450,"lead_sponsor_name":"Meril Life Sciences Pvt. Ltd.","has_results":false},{"nct_id":"NCT02750800","title":"Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)","phase":"","overall_status":"COMPLETED","enrollment_count":427,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04574492","title":"A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":413,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT07435272","title":"Kinesiophobia in Rheumatoid Arthritis: Associations With Functional Disability, Disease Activity, and Related Clinical Factors","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Minia University","has_results":false},{"nct_id":"NCT05090410","title":"Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Atsushi Kawakami","has_results":false},{"nct_id":"NCT03660059","title":"A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":385,"lead_sponsor_name":"Astellas Pharma China, Inc.","has_results":false},{"nct_id":"NCT02955212","title":"A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":338,"lead_sponsor_name":"AbbVie","has_results":true}],"total":50},"guidelines":[{"drug_id":"tocilizumab","guideline_body":"FDA label","recommendation":"TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"tocilizumab","guideline_body":"FDA label","recommendation":"TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"tocilizumab","guideline_body":"FDA label","recommendation":"TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of giant cell arteritis (GCA) in adult patients.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"tocilizumab","guideline_body":"FDA label","recommendation":"TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"tocilizumab","guideline_body":"FDA label","recommendation":"TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).","line_of_therapy":"adjunctive","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}